6.37
-0.60
(-8.61%)
At close: April 3 at 4:00:01 PM EDT
6.90
+0.53
+(8.32%)
Pre-Market: 5:45:53 AM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 3 |
| Avg. Estimate | -0.8 | -0.7 | -2.79 | -2.52 |
| Low Estimate | -0.84 | -0.75 | -2.88 | -2.75 |
| High Estimate | -0.75 | -0.65 | -2.69 | -2.17 |
| Year Ago EPS | -- | -- | -5.82 | -2.79 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | 0.00% | 0.00% |
Earnings History
| Currency in USD | 9/30/2024 | 12/31/2024 |
|---|---|---|
| EPS Est. | -2.72 | -0.59 |
| EPS Actual | -2.78 | -0.47 |
| Difference | -0.06 | 0.12 |
| Surprise % | -2.29% | 19.85% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.8 | -0.7 | -2.79 | -2.52 |
| 7 Days Ago | -0.54 | -0.55 | -2.3 | -2.34 |
| 30 Days Ago | -0.54 | -0.55 | -2.3 | -2.34 |
| 60 Days Ago | -0.55 | -0.56 | -2.28 | -2.33 |
| 90 Days Ago | -0.55 | -0.56 | -2.28 | -2.33 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | 1 | 1 | 2 | 1 |
| Down Last 30 Days | 1 | 1 | 2 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| MBX | -- | -- | 52.15% | 9.67% |
| S&P 500 | 6.69% | 6.80% | 9.98% | 14.34% |
Upgrades & Downgrades
| Initiated | Jefferies: Buy | 10/8/2024 |
| Initiated | JP Morgan: Overweight | 10/8/2024 |
| Initiated | Stifel: Buy | 10/8/2024 |
| Initiated | Guggenheim: Buy | 10/8/2024 |
Related Tickers
BCAX Bicara Therapeutics Inc.
11.83
-10.78%
ARTV Artiva Biotherapeutics, Inc.
2.5400
-11.19%
ZBIO Zenas BioPharma, Inc.
7.80
-7.47%
RAPP Rapport Therapeutics, Inc.
8.52
-14.46%
SEPN Septerna, Inc.
5.80
+5.55%
SER Serina Therapeutics, Inc.
5.49
+1.86%
MAZE Maze Therapeutics, Inc.
9.32
-10.13%
BNTC Benitec Biopharma Inc.
13.01
+3.67%
UPB Upstream Bio, Inc.
6.30
-2.93%
AARD Aardvark Therapeutics, Inc. Common Stock
8.69
-7.06%